Gallagher, Meghan
Bluebird Bio (United States)
3 papers on CoChat
Most cited papers
- Verified
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States
Herring, W. L., Gallagher, M. E., Shah, N., Morse, K., Mladsi, D., Dong, O. M., Chawla, A., Leiding, J. W., Zhang, L., Paramore, C., et al. (2024) · PharmacoEconomics
Hemoglobinopathies and Related DisordersHealth Systems, Economic Evaluations, Quality of Life
Cited by 18
- Verified
Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up
Kanter, J., Thompson, A. A., Kwiatkowski, J. L., Parikh, S., Mapara, M., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Gupta, A. O., Zhang, L., et al. (2023) · Blood
Hemoglobinopathies and Related DisordersNeurogenetic and Muscular Disorders Research
Cited by 15
- Verified
Value of a cure for sickle cell disease in reducing economic disparities
Graf, M., Tuly, R., Gallagher, M., Sullivan, J., & Jena, A. B. (2022) · American Journal of Hematology
Hemoglobinopathies and Related DisordersHealth Systems, Economic Evaluations, Quality of Life
Cited by 2
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free